Abbott Laboratories may see boost from St. Jude's acquisition: Barron's

NEW YORK (Reuters) - Abbott Laboratories is likely to see its shares rise again after trading range-bound for nearly a year on the back of its $25 billion acquisition of medical device-maker St. Jude Medical, Barron's said on Sunday.

Abbott Laboratories may see boost from St. Jude's acquisition: Barron's
Read More


Bagikan Berita Ini